To estimate the impact of amisulpride continued reimbursement in schizophrenia treatment on payer's budget in Poland.
Summary Objectives
To estimate the impact of amisulpride continued reimbursement in schizophrenia treatment on payer's budget in Poland.
Methods
The analysis was performed in 5-year time horizon from the payer (National Health Fund, NHF) perspective and payer+patient perspective. Only costs of medicines were included. On the base of IMS Health Poland sale data for years 2005 2010 linear regression was conducted to predict consumption and prevalence of antipsychotics in Poland. Cost data of reimbursed medicines were obtained from Ministry of Health and for not reimbursed medicines from internet portals. One-way sensitivity analysis were performed for the key input parameters.
Conclusion
Cost of treatment with amisulpride represent a small proportion of the total costs of schizophrenia treatment both from the payer and payer+patient perspectives estimated at approximately €213.87 million in 2010 and €241.81 million in 2014 respectively. Amisulpride costs accounts for €7.13 million in 2010 and €9.15 million in 2014 from the payer perspective and €7.26 million in 2010 and €9.32 million in 2014 from the payer+patient perspective. The declining trend in the share of amisulpride cost in total cost of schizophrenia and at the same time growing trend of amisulpride sale is noticeable. Amisulpride is an alternative therapeutic option that do not generate added cost of schizophrenia treatment in Poland and its reimbursement from public funds is justified.
Background
Schizophrenia is a chronic, severe, and disabling brain disorder that affects men and women between the late teens and the mid30s, but in rare cases, can appear in childhood. Symptoms can include hallucinations, disordered thinking, movement disorders, delusions and social withdrawal. The causes of the disease have not yet been determined, but current treatments can eliminate many of the symptoms and allow people with schizophrenia to live independent in the community.
The registry of patients treated for mental disorders indicated that there were approximately 126,000 patients treated for schizophrenia only in specialist centers in 2007 in Poland . National Health Fund (NHF) reports indicated that in 2005 health care expenditures alone for olanzapine account for around 3.0 percent of Poland's total health care expenses for drugs . Therefore an overview of substances and generics newly launched, current products and their market share in antipsychotics is essential from NHF perspective.
Methods
The analysis was performed in 5-year time horizon (2010) (2011) (2012) (2013) (2014) from the payer (National Health Fund, NHF) perspective and payer+patient perspective (co-payment).
Because of individual schizophrenia treatment schemes, frequently observed low compliance and heterogeneity in prevalence and morbidity data, implementation of budget impact (BIA) methods based on population and prevalence in the analysis was not possible. Health care expenses for schizophrenia in Poland where therefore calculated based on predicted antipsychotics sales over a span of the next five years. Sales data, when there is no possibility to estimate on population and prevalence, is the best information on the past expenses and optimal basis for the prognosis. 
Conclusions
Our fi ndings suggest that the cost of treatment with amisulpride are at a reasonable level and represent a small proportion of the total costs of schizophrenia treatment both from the payer perspective and common payer+patient perspective. The declining trend in the share of amisulpride cost in total cost of schizophrenia is noticeable. Amisulpride is an alternative therapeutic option of schizophrenia treatment in Poland and its reimbursement from public funds is justifi ed.
